Register
Login:
Share:
Email Facebook Twitter


Angus Energy announces transformational joint venture with Cuadrilla & Lucas Energy
Aim-listed Mongolian explorer Petro Matad to drill four wells in 2018


Avacta Share Chat (AVCT)



Share Price: 62.50Bid: 60.00Ask: 65.00Change: 0.00 (0.00%)No Movement on Avacta
Spread: 5.00Spread as %: 8.33%Open: 62.50High: 62.50Low: 62.50Yesterday’s Close: 62.50


Share Discussion for Avacta


Thread View

Please login or register to post a message on Share Chat.

Posts per page:


wintzy
Posts: 409
Off Topic
Opinion:No Opinion
Price:76.50
RE: AVCT at ShareSoc Manchester blo..
7 Aug '17
DD77...does today's RNS alleviate your concerns?
 
DD77
Posts: 350
Off Topic
Opinion:No Opinion
Price:85.00
RE: AVCT at ShareSoc Manchester blo..
25 Jul '17
Sharetalk, thanks for the blog. In summary, it does tend to mirror mine and no doubt other investors thoughts on the company. The general sentiment is that the board, with Alistair at the helm, are very competent and progress has been positive. However, the lack of visibility to what the deals they have done ultimately entail, leave us very much in limbo with the share, which is probably reflected in the current SP. I don't think we will see any clarity to this for another year or 2, as things don't tend to move quickly in the pharmaceutical sector. That said, I remain fairly positive about the company, and eagerly anticipate their next results/trading update
share_talk
Posts: 1,439
Off Topic
Opinion:No Opinion
Price:88.00
AVCT at ShareSoc Manchester blog
14 Jul '17
http://www.share-talk.com/share-news/sharesoc-company-seminar-doubletree-hilton-hotel-manchester-11-07-2017/

We attended this investor's evening with CMCL and AVCT earlier this week and here is our short blog on the night's proceedings. Be interested to hear any feedback from shareholders.

Share Talk
Valuespotter
Posts: 29
Observation
Opinion:No Opinion
Price:94.00
Heading for 1 year high
23 May '17
Abcam supplies "protein research tools to life scientists" from a catalogue of antibody products. Abcam's mkt cap is nearly £2 bn
Avacta's mkt cap is £60 million. It is now very clear that its affimer technology works, representing a giant leap forward over traditional antibody-based reagents and therapeutics. Antibody-based therapeutics - a far more valuable market than diagnostics - is now wide open to Avacta's new technology. Avacta's share price is getting closer to the 1 year high. Much more to come
https://www.google.co.uk/?gws_rd=ssl#q=avct+share+price
Giveusaclue
Posts: 206
Observation
Opinion:No Opinion
Price:89.50
Good News
22 May '17
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and research reagents, is pleased to announce that two leading US biotech companies have separately taken exclusive rights to Affimer reagents for research and development use, to support their respective drug development programmes.
Wisheyedbortum
Posts: 665
Observation
Opinion:Strong Buy
Price:85.00
AVCT.
26 Apr '17
Nice to see Avacta climbing for a change. A few more announcements like the last one and the £2.00 looks a distinct possibility.
Wisheyedbortum
Posts: 665
Observation
Opinion:Strong Buy
Price:80.00
News.
24 Apr '17
Of course, the slight drawback is the undisclosed finances involved. We don't know if they are game changing amounts or not, but the fact that it's one of the big three is very encouraging and more of the same can only be a good thing. My guess would be Novartis.
gibsonj45
Posts: 250
Observation
Opinion:No Opinion
Price:75.50
RE: Great News...
24 Apr '17
Yes it could really take off from here, a "key inflection point".
Wisheyedbortum
Posts: 665
Observation
Opinion:Strong Buy
Price:69.50
Great News...
24 Apr '17
....this morning, the first of many we hope.




Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk






Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.